20-EPI-vitamin D3 analogs: Potent modulators of proliferation and differentiation of breast cancer cell lines in vitro

Advances in Experimental Medicine and Biology

Volumn 399, Issue , 1996, Pages 53-70

  Elstner, E ^a   Heber, D ^a   Koeffler, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL DERIVATIVE; LEXACALCITOL; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; BREAST CARCINOMA; CALCIUM MOBILIZATION; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERCALCEMIA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029959504     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-1151-5_5     Document Type: Conference Paper

References (124)

1. Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. New Engl J Med 1989; 320:980-991.
2. Garland FC, Garland CF, Gorham ED, Young JF: Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Preventive Medicine 1990; 19:614-622.
3. Gorham ED, Garland FC, Garland CF: Sunlight and breast cancer incidence in the USSR. International J of Epidemiology 1990; 19:820-824.
4. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in breast cancer. Cancer Res 1987; 47:6793-6799.
5. 3. Clin Endocrinol 1980; 13:267-272.
6. 3 receptors in human skin biopsies. J Clin Endocrinol Metab 1980; 51:1463-1465.
7. Colston KW, Berger U, Coombes RC: Possible role for vitamin D in controlling breast cancer cells proliferation. Lancet 1989;28:188-191.
8. Becker AR, McDonnell DP, Hausler MR, Pike JW, Shine J, O'Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Nat Acad Sci USA 1988; 85:3294-3298.
9. 3 receptors: gene regulation and genetic circuitry. FASEB J 1988; 2:3043-3053.
10. Haussler MR, Mangelsdorf D, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, Baker AR, Shine J, McDonnell DP, Hughes M, Weigel NL, O'Malley BW, Pike JW: Molecular biology of the vitamin D hormone. Recent Prog Horm Res 1988; 44:263-305.
11. 3 receptor in human epithelial cancer cell lines. Cancer Res 1982; 42:856-859.
12. 3 receptor in breast cancer cells. Lancet 1979; Dec 22/29:1335-1336.
13. 3 metabolites. Cancer Res 1983; 43:443-447.
14. 3. Proc Natl Acad Sci USA 1981; 76:4990-4994.
15. Colston KW, Chander SK, Mackay AG, Coomes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacology 1992; 44:693-702.
16. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB: Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994; 54:3413-21.
17. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Coombes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 1991; 337:701-702.
18. 3. Cancer Research 1987; 47:21-25.
19. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Acad Sci USA 1983; 80:201-204.
20. 3 on metastasis of rat ascites hepatoma K-231. Br J Cancer 1984; 50:123-125.
21. 3 prolong survival time of leukemic mice. Proc Natl Sci USA 1990; 87:3929-3932.
22. 3 on the morphology of human breast cancer cell line BT 20. Differentiation 1989; 40:63-69.
23. 3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmac 1991; 42:1569-1575.
24. Mathiasen IS, Colston KW, Binderup L: EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Molec Biol 1993; 46:365-371.
25. 3 receptor. Cancer Res 1984; 44:2103-2109.
26. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Common 1981; 102:937-943.
27. 3 receptor and induction of differentiation by the hormone. J Steroid Biochem 1988; 29:265-270.
28. 3: differential effects on leukemic cell growth, differentiation, and intestinal absorption. Cancer Res 1990; 50:6857-6864.
29. 3 analogue, stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Dermatol Res 1990; 282:164-167.
30. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR: Induced differentiation in a human promyelocytylic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98:391-398.
31. 3 (calcitrol): A morphologic, phenotypic, and functional analysis. Blood 1984; 64:1110-1115.
32. 3 metabolites on normal and leukemic bone marrow cells in vitro. Int J Cell Cloning 1984; 2:227-242.
33. 3 and its fluorinated analogues. Cancer Res 1984; 44:5624-5628.
34. Koeffler HP: Study of normal and abnormal hematopoiesis using human leukemic cell lines. UCLA Symposia on Molecular and Cellular Biology. New Series, Vol.9. New York, New York: Alan R Liss, Inc 1983; 179-195.
35. 3 and the hematopoietic system. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV eds. Vitamin D: Chemical, biochemical and Clinical Update. Berlin, Germany: Walter de Gruyter 1985; 167-176.
36. 3 by normal human macrophages. In:Norman AW, Schaefer K, Grigoleit HG, Herrath DV eds. Vitamin D:Chemical, Biochemical and Clinical Update. Berlin, Germany: Walter de Gruyter 1985; 61-62.
37. 3 receptor in pulmonary alveolar macrophages. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV eds. Vitamin D: Chemical, Biochemical and Clinical Update. Berlin, Germany:Walter de Gruyter 1985; 127-128.
38. 3 and the hematopoietic systems. In: Gale RP and Golde DW eds. Leukemia: Recent Advances in Biology and Treatment. Vol.28. New York, New York: Alan R. Liss, Inc. 1985; 399-413.
39. Koeffler HP: Study of differentiation and proliferation of leukemic cells using myeloid leukemia lines. In: Bloomfield CD ed. Adult Leukemias 2. The Hague. Netherlands: Martinus Nijhoff Publishers 1985; 27-68.
40. Koeffler HP: Vitamin D: Myeloid differentiation and proliferation. Current Trends in Human Leukemia VI. In: Gallo R, Neth H, Moore M. eds. Hematology and Blood Transfusion Vol.29. Modern Trends in Human Leukemia. Berlin, Germany: Springer-Verlag 1985; 409-417.
41. 3 and τ-interferon. In: Cohen DV, Martin TV, Meunier PJ, eds. Calcium Regulation and Bone Metabolism: Basic and clinical aspects. Vol 9. amsterdam, Holland: Excerpta Medica 1987; 371-376.
42. 3 with normal and abnormal hematopoiesis. In: Aarbakke J, Chiang PK, Koeffler HP eds. Tumor Cell Differentiation, Biology and Pharmacology. Clifton, New Jersey: The Humana Press 1987; 137-157.
43. Lubbert M, Koeffler HP: Leukemic cell lines as a paradigm for myeloid differentiation. In: Olsson, L. ed. in chief. Cancer Reviews, Vol 10. Copenhagen, Denmark: Munksgaard International Publishers, Ltd 1988; 33-62.
44. 3 receptor ligand specificity and biological activity in the chick and human promyelocytic (HL-60) cells. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV eds. Vitamin D:Molecular, Cellular and clinical Endocrinology. Berlin, West Germany: Walter de Gruyter 1988; 433-434.
45. 3: Role in myelodysplastic syndromes and leukemia. In: Proceedings of International Symposium on Myelodysplastic Syndromes: Pathophysiology and Treatment Kyoto, Japan. The Netherlands: Elsevier Science Publishers 1988; 173-186.
46. Paquette RL, Koeffler HP: Myelodysplastic Syndrome: Culture Studies and Therapy. In: Mufti GJ and Glaton DAG eds. Churchill Livingstone Monograph of Myelodysplastic Syndromes. Amsterdam, The Netherlands: Elsevier Science Publishers 1992.
47. Koeffler HP, Norman AW: Interaction between the hematopoietic system and the vitamin D endocrine system. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV eds. Vitamin D: Molecular, cellular and clinical endocrinology. Berlin: Walter De Gruyther 1988; 263-266.
48. 3. In: Ahserson GL, Zembala M. eds. The Human Monocyte. London, England: Academic Press Limited 1989; 345-351.
49. Miller CW, Koeffler HP: In vivo and in vitro differentiation of myeloid leukemic cells. In: Mauer AM, ed. The biology of Human Leukemia. Baltimore, Maryland: Johns Hopkins Press 1990; 152-176.
50. 3 in hematopoietic cells. In: Peterlik M, Bronner F. eds. Molecular and cellular regulation of calcium and phosphate metabolism. New York. New York: Alan R. Liss, Inc. 1990; 81-97.
51. 3 and hematopoietic cells. In: Vitamins and Cancer Prevention. Laidlaw SA, Swendseid ME eds. New York, New York: Wiley and Liss. Inc. 1991; 91-102.
52. 3 in human mononuclear cells. Nutrient Modulation of the Immune response. Marcel Dekker, Inc., 1992; 3-29.
53. Kizaki M, Koeffler HP: Differentiation inducing agents in the treatment of MDS. Seminars in Oncology. Myelodysplastic Syndromes 1992; 95-105.
54. Tobler A, Koeffler HP: Differentiation inducers and their potential use in the treatment of acute myelogenous leukemia (MJ Waring and BAJ Ponder, ed.) Kluwer Academic Publishers 1991; 163-183.
55. Paquette R, Koeffler HP: Differentiation therapy for myelodysplastic syndromes. North American Clinics of Hematology (HP Koeffler, ed.), W.B. Sunders Company 1992; 687-706.
56. Akashi M, Koeffler HP: Differentiation therapy in leukemia. Focus on CML/MM. KK Standard McIntyre Co. Tokyo, Japan. 1994; 5-7.
57. 3 analogs. In: Hematology and blood Transfusion, Buechaer, Hiddenmann (eds), Springer-Verlag, accepted, 1994.
58. Koeffler HP: Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 1983;62:709-721.
59. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treatment Rep 1985; 69(12):1399-1407.
60. 3 by human pulmonary macrophages. Biochem Biophys Res Commun 1985; 127:596-603.
61. Koeffler HP, Yelton L, Prokocimer M, Hirji K: Study of differentiation of fresh myelogenous leukemic cells by compounds that induce a human promyelocytic leukemic line (HL-60) to differentiate. Leukemia Res 1985; 9:73-81.
62. Munker R, Norman A, Koeffler HP: Vitamin D compounds: Effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986; 78:474-480.
63. 3. Arch Biochem Biophys 1986; 251:222-231.
64. Munker M, Munker R, Saxton RE, Koeffler HP: Effect of recombinant monokines, lymphokines and other agents on clonal proliferation of cells from human lung cancer lines. Cancer Res 1987; 47:4081-4085.
65. 3 inhibits γ- interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987; 84:3385-3389.
66. 3 by interferon gamma stimulated normal human and alveolar bone marrow macrophages. J Bio Chem 1987; 262(23):10931-10937.
67. 3 metabolism by human T- lymphotropic virus transformed lymphocytes. J Clin Endocr Metab 1987; 5:519-526.
68. 3: metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endoc and Metab 1987; 64:1-9.
69. 3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocr Metab 1987; 65:1201-1209.
70. Tobler A, Koeffler HP: Differentiation of human acute myelogenous leukemia cells: Therapeutic possibilities. Acta Haematologica 1987; (78)1:127-135.
71. 3 in normal human peripheral blood lymphocytes. J Clin Invest 1987; 79:1700-1705.
72. Lubbert M, Koeffler HP: Mycloid cell lines: Tools for studying differentiation of normal and abnormal hematopoietic cells. Blood Reviews 1988; 2:121-133.
73. 3 modulates the expression of a lymphokine (granulocyte-monocyte colony stimulating factor) post-transcriptionally. J Clin Invest 1988; 81:1819-1823.
74. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 1989; 74:82-93.
75. 3 receptor. Mol and Cellul Endo 1990; 70:1-11.
76. 3 by hematopoietic cells. Progress in Clinical and Biological Research 1990; 332:81-97.
77. 3: Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Research 1990; 50:6857-6864.
78. 3 receptor RNA: expression in hematopoietic cells. Blood 1991;77:1238-1247.
79. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991; 78:75-82.
80. 3. J Med Chem 1991; 34:2452-2463.
81. Kizaki M, Koeffler HP: differentiation-inducing agents in the treatment of myelodysplastic syndromes. Seminars in Oncology 1992; 19:95-105.
82. 3 production by cultured porcine alveolar macrophages. Mol Cell Endo 1991; 75:163-167.
83. 3 analogs. Proceedings of the Eighth Workshop on Vitamin D 1991; 146-154.
84. 3 vitamin gene. Proceedings of the Eighth Workshop on Vitamin D 1991; 165-166.
85. 3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages. Leukemia 1993; 7(10):1525-1530.
86. 3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leukemia Research 1994; 18(6):453-463.
87. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 1994; 84(6):1960-1967.
88. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leukemia Research 1995; 19:65-72.
89. 3 response element. Leukemia Research, in press, 1994.
90. 3 analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation in human estrogen receptor (ER)-positive and ER-negative breast cancer cell lines in vitro. Cancer Research, in press, 1995.
91. 3. Preferential activity in inducing differential of human leukemia cell HL-60 in vitro. Proc Natl Acad Sci USA 1987; 84:2610.
92. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84:1968-1968, 1994.
93. Kiguchi, K., Giometti, C., Chubb, C. H., Fujiki, H., and Huberman, E.: Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Biochem and Biophysical Research Communications, 189:1261-1267, 1992.
94. Sheehan, D. C.: Theory and practice of histotechnology, 2nd ed C. V. Mosby Company. St. Lous, p.209. 1980.
95. Bacus, S. S., Kiguchi, K., Chin, D., King, C. R., and Huberman, E. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Molecular Carcinogenesis, 3: 350-362, 1990.
96. Martin, S. J. and Cotter T. G. Apoptosis of human leukemia: induction, morphology, and molecular mechanisms. In: Apoptosis II: Molecular basis of apoptosis in disease. Cold Spring Harbor Laboratory Press, p.1, 1994.
97. Sellins, K. S., and Cohen, J. J.: Gene induction by Gamma-irradiation leads to DNA fragmentation in lymphocytes. J. Immunology, 139: 3199-3206, 1987.
98. Said, J. W., Pinkus, G. S., Lones, M. A., Preston, M., and Shintaku, I. P. Expression of bcl-2 oncogene protein in malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas of T-cell phenotype. Applied Immunohistochemistry, 1: 108-114, 1993.
99. Lones, M. A., Said, J. W., Pinkus, G. S. Bcl-2 oncogene protein in preferentially expressed in Reed Sternberg cells in Hodgkin's disease of modular sclerosis subtype. Am J. Clin Pathol. (in press), 1994.
100. Walts, A. E., Said, J. W., and Koeffler, H. P. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Modern Pathol. (in press), 1994.
101. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
102. Bartck, J. Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-9, 1990.
103. Miller, C. W., Chumakov, A., Said, J., Chen, D. L., Aslo, A., and Koeffler, H. P. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8: 1815-1824, 1993.
104. Midland, M.M., Plumet, Y. and Okamura, W.H. Effect of C20 stereochemistry on the conformational profile of the side chains of vitamin D analogs. Bioorganic and Medicinal Chemistry Letters, 3: 1799-1804, 1993.
105. Mangelsdorf, DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR: Induced differentiation in a human promyelocytylic leukemia cell line (HL 60): receptor-mediated maturation to macrophage-like cells. J CellBiol 1984; 98:391-398.
106. Collins, S. J., Ruscetti, F. W., Gallagher, R. E., and Gallo, R. C. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J. Exp. Med., 149: 969-977, 1979.
107. Douer, D., and Koeffler, H. P. Inhibition of the clonal growth of human myeloid leukemia cells. J. Clin. Invest. , 69: 277-283.
108. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542.
109. Raff, M. C. Social control on cell survival and cell death. Nature (Lond.), 356: 397-400, 1992.
110. Oltval, Z. N., and Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell. 79: 189-192, 1994.
111. Vaux, D. L., Cory, S., and Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature,335: 440-442, 1988.
112. Hockenbery, D., Nu-ez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl- 2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348: 334-339, 1990.
113. Hockenbery, D. M. The bcl-2 oncogene and apoptosis. Seminars in Immunology, 4: 413-420, 1992.
114. McDonnell, T. J., Deane, N., Platt, F.M., Nunez, G., Jaeger, U., McKearn, J. P., and Korsmcyer, S. J. Bcl-2 immunoglobin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
115. El-Deiry, W. S., Tokino, T, Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, W. E., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
116. Herper, J. W., Adam G. R., Wei, N, Keyomarsi, K., and Elledge, S. J. The p21 cdk- interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
117. Symonds, H., Krall, L., Remington, L., Saenz-Robles, L., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresse tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
118. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin- 6. Nature (Lond.). 352: 345-347, 1991.
119. Show, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
120. Crawford, L. V., Pim, D. C., And Lamb, P. The cellular protein p53 in human tumours. Mol. Biol. Med., 2: 261-272, 1984.
121. Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., and Domenico, D. p53 in breast cancer. Int. J. Cancer. 41: 178-183, 1988.
122. Riou, G., L, M. G., Travagli, J. P., Moll, U. M., and Levine, A. J. Poor prognosis of p53 nuclear overexpression and mutation in inflammatory breast carcinoma. Proc. Amer. Assoc. Canc. Res., 35: Abstract 1314, 1994.
123. Mehta, R. R., Graves, J. M., and Das Gupta, T. K. p53 levels and breast tumor metastasis in experimental animals. Proc. Amer. Assoc. Canc. Res., 35: Abstract 286, 1994.
124. Moll, U. M., Riou, G., and Levine, J. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc. Natl. acad. Sci. USA, 89: 7262-7266, 1992.